Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Spyre Therapeutics, Inc has 88.06M shares outstanding.

As of June 30, 2026, Spyre Therapeutics, Inc maintains a current ratio of 18.53, meaning it holds 18.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Spyre Therapeutics, Inc posted a negative return on equity (ROE) of -28.52, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -20.90, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 92.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Spyre Therapeutics, Inc generated - - in revenue and converted that into -156.61M in net income, yielding earnings per share of -2.09. EBITDA reached -176.23M, while operating income came in at -237.50M.

These figures are as of June 30, 2026. Total book value stands at 835.66M, with working capital of 971.32M providing operational flexibility.

Spyre Therapeutics, Inc produced -182.89M in operating cash flow over the twelve months ended June 30, 2026.

Spyre Therapeutics, Inc's most recent stock split took place on September 8, 2023 with a 25:1 split ratio.